{"id":38369,"date":"2026-07-09T21:54:05","date_gmt":"2026-07-09T21:54:05","guid":{"rendered":"https:\/\/selmiswiss.com\/?post_type=product&#038;p=38369"},"modified":"2026-07-09T22:17:42","modified_gmt":"2026-07-09T22:17:42","slug":"pnc-27","status":"publish","type":"product","link":"https:\/\/selmiswiss.com\/fr\/produit\/pnc-27\/","title":{"rendered":"PNC-27"},"content":{"rendered":"<div class=\"selmi-peptide-sheet\">\n<div class=\"selmi-peptide-header\">\n<div class=\"selmi-peptide-title\">PNC-27<\/div>\n<div class=\"selmi-peptide-category\">Recherche en oncologie<\/div>\n<\/p><\/div>\n<div class=\"selmi-peptide-grid selmi-peptide-grid-top\">\n<section class=\"selmi-peptide-main\">\n<div class=\"selmi-peptide-section\">\n<h3>M\u00c9CANISME D&rsquo;ACTION<\/h3>\n<p>Peptide chim\u00e9rique p53-p\u00e9n\u00e9tratine de 32 r\u00e9sidus. Domaine de liaison \u00e0 HDM-2, r\u00e9sidus 12 \u00e0 26 de p53, fusionn\u00e9 \u00e0 une s\u00e9quence de p\u00e9n\u00e9tratine permettant la p\u00e9n\u00e9tration cellulaire. Il se lie de mani\u00e8re s\u00e9lective \u00e0 l&rsquo;HDM-2 surexprim\u00e9 sur les membranes des cellules canc\u00e9reuses, mais non exprim\u00e9 \u00e0 la surface des cellules normales, favorisant ainsi la formation de pores dans la membrane et la n\u00e9crose s\u00e9lective des cellules tumorales.  <\/p>\n<\/p><\/div>\n<div class=\"selmi-peptide-section\">\n<h3>PRINCIPAUX AVANTAGES<\/h3>\n<ul>\n<li>Destruction s\u00e9lective des cellules canc\u00e9reuses sans endommager les cellules saines.<\/li>\n<li>Activit\u00e9 contre les lign\u00e9es cellulaires du cancer du sein, de l&rsquo;ovaire, du col de l&rsquo;ut\u00e9rus et du pancr\u00e9as.<\/li>\n<li>M\u00e9canisme novateur, diff\u00e9rent de la chimioth\u00e9rapie conventionnelle.<\/li>\n<li>Capacit\u00e9 \u00e0 contourner les m\u00e9canismes de r\u00e9sistance.<\/li>\n<\/ul><\/div>\n<\/section>\n<aside class=\"selmi-peptide-dosing\">\n<h3>LES R\u00c9SULTATS D\u00c9CRITS CI-DESSUS ONT \u00c9T\u00c9 OBTENUS EN RESPECTANT LA POSOLOGIE ET LE PROTOCOLE INDIQU\u00c9S CI-DESSOUS<\/h3>\n<h4>1 mg\/jour par voie sous-cutan\u00e9e<\/h4>\n<p><strong>Contenance du flacon :<\/strong><br \/>5 mg<\/p>\n<p><strong>Fr\u00e9quence :<\/strong><br \/>Une fois par jour<\/p>\n<p><strong>UI \/ Dose :<\/strong><br \/>40 UI<\/p>\n<p><strong>Reconstitution :<\/strong><br \/>Reconstituer avec 2 ml d&rsquo;eau bact\u00e9riostatique. 40 UI = 1 mg. <\/p>\n<p><strong>Cycle :<\/strong><br \/>Protocole exp\u00e9rimental de recherche. Non destin\u00e9 \u00e0 un usage clinique. <\/p>\n<\/aside><\/div>\n<div class=\"selmi-peptide-grid selmi-peptide-grid-info\">\n<section class=\"selmi-peptide-box\">\n<h3>EFFETS SECONDAIRES ET S\u00c9CURIT\u00c9<\/h3>\n<p>Ce n&rsquo;est encore qu&rsquo;au stade de la recherche. Aucun profil de s\u00e9curit\u00e9 humaine n&rsquo;a \u00e9t\u00e9 \u00e9tabli. <\/p>\n<\/section>\n<section class=\"selmi-peptide-box selmi-peptide-box-alt\">\n<h3>NOTES DE RECHERCHE ET CLINIQUES<\/h3>\n<p>Bowne et al. (2008) : le PNC-27 a d\u00e9truit 100 % des cellules canc\u00e9reuses du sein et plus de 99 % des cellules canc\u00e9reuses du pancr\u00e9as in vitro en l&rsquo;espace d&rsquo;une heure. S\u00e9lectivit\u00e9 confirm\u00e9e pour les cellules tumorales exprimant HDM-2. Phase I en cours de planification.   <\/p>\n<\/section><\/div>\n<section class=\"selmi-peptide-profile\">\n<h3>PROFIL RECHERCH\u00c9 :<\/h3>\n<p><em>Protocoles de recherche ax\u00e9s sur l&rsquo;oncologie et programmes compl\u00e9mentaires d&rsquo;oncologie int\u00e9grative.<\/em><\/p>\n<\/section>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<div class=\"selmi-div-disclaimer\"><span class=\"selmi-disclaimer-text\">\u00c0 UTILISER EXCLUSIVEMENT \u00c0 DES FINS DE RECHERCHE PR\u00c9CLINIQUE \u2014 NON APPROUV\u00c9 POUR UNE UTILISATION CHEZ L&rsquo;HOMME.<\/span><\/div>\n<ul>\n<li>Destruction s\u00e9lective des cellules canc\u00e9reuses sans endommager les cellules saines.<\/li>\n<li>Activit\u00e9 contre les lign\u00e9es cellulaires du cancer du sein, de l&rsquo;ovaire, du col de l&rsquo;ut\u00e9rus et du pancr\u00e9as.<\/li>\n<li>M\u00e9canisme novateur, diff\u00e9rent de la chimioth\u00e9rapie conventionnelle.<\/li>\n<li>Capacit\u00e9 \u00e0 contourner les m\u00e9canismes de r\u00e9sistance.<\/li>\n<\/ul>\n","protected":false},"featured_media":38375,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[1119],"product_tag":[1102],"class_list":["post-38369","product","type-product","status-publish","has-post-thumbnail","product_cat-guerison-et-reparation-des-tissus-peptides","product_tag-peptides","first","instock","taxable","shipping-taxable","purchasable","product-type-simple"],"acf":[],"_links":{"self":[{"href":"https:\/\/selmiswiss.com\/fr\/wp-json\/wp\/v2\/product\/38369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/selmiswiss.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/selmiswiss.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/selmiswiss.com\/fr\/wp-json\/wp\/v2\/comments?post=38369"}],"version-history":[{"count":1,"href":"https:\/\/selmiswiss.com\/fr\/wp-json\/wp\/v2\/product\/38369\/revisions"}],"predecessor-version":[{"id":38381,"href":"https:\/\/selmiswiss.com\/fr\/wp-json\/wp\/v2\/product\/38369\/revisions\/38381"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/selmiswiss.com\/fr\/wp-json\/wp\/v2\/media\/38375"}],"wp:attachment":[{"href":"https:\/\/selmiswiss.com\/fr\/wp-json\/wp\/v2\/media?parent=38369"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/selmiswiss.com\/fr\/wp-json\/wp\/v2\/product_brand?post=38369"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/selmiswiss.com\/fr\/wp-json\/wp\/v2\/product_cat?post=38369"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/selmiswiss.com\/fr\/wp-json\/wp\/v2\/product_tag?post=38369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}